Neuroblastoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Neuroblastoma – Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects
- The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroblastoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAbility Pharmaceuticals SL
Actuate Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adicet Bio Inc
Advanced Accelerator Applications SA
Advanced Innovative Partners Inc
Alaunos Therapeutics Inc
Alissa Pharma
Anima Biotech Inc
Aptorum Group Ltd
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
AstraZeneca Plc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Bayer AG
Baylor College of Medicine
Beijing zhikangbo Medical Oncology Research Co Ltd
Belarusian Research Center for Pediatric Oncology Haematology and Immunology
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
Biocad
BioEclipse Therapeutics Inc
Biogenera SpA
Biosceptre International Ltd
Bristol-Myers Squibb Co
Canthera Discovery
Cartexell Inc
Cebiotex SL
Cellectar Biosciences Inc
Center for Research and Advanced Studies of the National Polytechnic Institute
Centre Hospitalier Universitaire Sainte-Justine
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Children's Hospital of Philadelphia
Children's National Research Institute
Chiome Bioscience Inc
Clarity Pharmaceuticals Ltd
Collaborations Pharmaceuticals Inc
CorMedix Inc
CSPC Pharmaceutical Group Ltd
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Day One Biopharmaceuticals Inc
DEKK-TEC Inc
Edison Oncology Holding Corp
Eli Lilly and Co
Epigene Therapeutics Inc
Eureka Therapeutics Inc
Exelixis Inc
Expression Therapeutics Inc
F. Hoffmann-La Roche Ltd
GAiA BioMedicine Inc
Garvan Institute of Medical Research
Gate2Brain SL
Gibson Oncology LLC
Ginkgo BioWorks Inc
ImmunoAct Pvt Ltd
Innovent Biologics Inc
Institute of Biotechnology and Pharmaceutical Research
Invenra Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Jubilant DraxImage Inc
KC Pharma LLC
Kian Immune Cell Co
Kite Pharma Inc
Kronos Bio Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
LintonPharm Co Ltd
Ludwig-Maximilians-University Munich
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Medosome Biotec LLC
Merck & Co Inc
Nanjing CART Medical Technology Co Ltd
Nanogenics Ltd
NanoPharmaceuticals LLC
National Cancer Institute US
Nektar Therapeutics
Nobelpharma Co Ltd
Novartis AG
NovoMedix LLC
Nurix Therapeutics Inc
Nuvalent Inc
OBI Pharma Inc
OGD2 Pharma SAS
Ohara Pharmaceutical Co Ltd
Oncolys BioPharma Inc
Onconova Therapeutics Inc
OncoTherapy Science Inc
Open Therapeutics LLC
Orgenesis Inc
Orphelia Pharma SAS
Osaka University
Peel Therapeutics Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Perspective Therapeutics Inc
Pfizer Inc
Progenics Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
PYC Therapeutics Ltd
Recombio SL
Recordati SpA
Repare Therapeutics Inc
Rophibio Inc
Sapience Therapeutics Inc
SciTech Development LLC
Senhwa Biosciences Inc
Shenzhen Geno-Immune Medical Institute
Shionogi & Co Ltd
Sichuan Huiyu Pharmaceutical Co Ltd
Sinobioway Cell Therapy Co Ltd
SMTPH Ltd
Sorrento Therapeutics Inc
St. Jude Children’s Research Hospital Inc
Statera Biopharma Inc
Stemsynergy Therapeutics Inc
Stony Brook University
Tactiva Therapeutics LLC
Talus Bioscience Inc
TC BioPharm Ltd
Tel Aviv University
The Translational Genomics Research Institute
Trevarx Biomedical Inc
TroBio Therapeutics Pty Ltd
U.S. National Institutes of Health
UGISense AG
UNC Lineberger Comprehensive Cancer Center
University Medical Center Utrecht
University Medicine Greifswald
University of Chicago
University of Kansas
University of Nebraska Medical Center
US WorldMeds LLC
UTC Therapeutics Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Y-mAbs Therapeutics Inc
Zhujiang Hospital of Southern Medical University
Zr Pharma & Gmbh